Tenaya Therapeutics Rallies 8.5% as Gene‑Editing Cardio Pipeline Gains Investor Confidence
Tenaya Therapeutics (TNYA) surges 8.47% amid market volatility, as gene‑editing and cell‑based heart‑disease therapies spark renewed investor interest and a potential upside toward its 200‑day support level.
- TENAYA THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read